Abstract: Provided is a method for preventing, alleviating, or treating a viral infectious disease or a respiratory disease, comprising administering a composition containing vesicles derived from Lactobacillus paracasei as an active ingredient to a subject in need thereof, wherein the vesicles may be orally administered and delivered to the lung to suppress a respiratory disease, administered to a COVID-19 virus- or influenza virus-infected model to suppress the replication of the COVID-19 virus and clinical symptoms caused by the influenza virus.

Abstract: Provided is a pharmaceutical composition for the prevention, alleviation, or treatment of inflammatory diseases, metabolic diseases, and cancer, comprising a Streptococcus pyogenes culture broth or a protein isolated from the culture broth as an active ingredient. The inventors of the presently claimed subject matter confirmed that, when administered to inflammatory disease, metabolic disease, and cancer models, a Streptococcus pyogenes culture broth or a protein isolated from the culture broth exhibited anti-inflammatory, anti-obesity, liver function-improving, and anticancer effects, and thus the Streptococcus pyogenes culture broth or the protein isolated from the culture broth according to the presently claimed subject matter can be effectively used to develop a drug, a health functional food, an inhalant, a cosmetic composition, or the like for preventing inflammatory diseases, metabolic diseases, and cancer, or alleviating or treating symptoms thereof.

Abstract: Provided is a method for alleviating, preventing or treating a neurodevelopmental disease, neurologic disease, or psychiatric disease, comprising administering to a subject in need thereof a composition including, as an active ingredient, vesicle derived from Micrococcus luteus, wherein the disease including Alzheimer's disease, Parkinson's disease, amyotropic lateral sclerosis, Huntington's disease, epilepsy, multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, diabetic neuropathy, autism spectrum disorder, attention deficit hyperactivity syndrome, major depressive disorder, bipolar disorder, anxiety disorders, schizophrenia, obsessive compulsive disorder, post-traumatic stress disorder, dissociative disorders, eating disorders, substance use disorder, and personality disorders occurring as a result of neurogenesis dysfunction or neuroinflammation.

Abstract: Provided is a method for preventing, alleviating or treating an ocular disease including administering a composition containing vesicles derived from Micrococcus luteus as an active ingredient wherein the vesicles are delivered to the central nervous system including the retina through the blood-brain barrier (BBB); when epithelial cells and macrophages were treated with the vesicles, not only is the secretion of an inflammatory mediator by a biological causative factor considerably inhibited, but also NLRP3 protein expression by a biological causative factor is inhibited; and when the vesicles are administered to a rabbit model with an ocular disease caused by oxidative stress, retinal degeneration is significantly inhibited, thus the vesicles derived from Micrococcus luteus can be used for a composition for preventing, alleviating or treating an age-related ocular disease and an inflammatory ocular disease, including a pharmaceutical or health functional food composition.

Abstract: The claimed subject matter relates to Lactobacillus paracasei-derived extracellular vesicles and a use thereof, and more particularly, to a composition for alleviating, preventing and treating an ocular disease, which includes Lactobacillus paracasei-derived extracellular vesicles as an active ingredient, capable of effectively inhibiting the occurrence of an ocular disease caused by oxidative stress-mediated cell senescence.

Abstract: The present invention relates to vesicles derived from bacteria of the genus Catenibacterium and a use thereof, and the inventors experimentally confirmed that the vesicles were significantly reduced in samples obtained from patients with a malignant disease such as colon cancer, pancreatic cancer, cholangiocarcinoma, ovarian cancer, bladder cancer or lymphoma, a cardiovascular disease such as myocardial infarction, atrial fibrillation, variant angina or stroke, diabetes, Parkinson's disease, and depression, compared with a normal individual, and that when vesicles isolated from the strain were administered, the secretion of inflammatory mediators caused by pathogenic vesicles, such as E. coli-derived vesicles, was significantly inhibited.

Abstract: The present invention relates to a pharmaceutical and food composition for treating, preventing, or alleviating a metabolic disease, containing, as an active ingredient, extracellular vesicles derived from Akkermansia muciniphila. The composition of the present invention can be used as a pharmaceutical/food composition and the like for treating, preventing, or alleviating metabolic diseases, in particular metabolic diseases such as obesity, diabetes, hyperlipidemia, arteriosclerosis, and hypertension, occurring or exacerbated due to a high fat diet. In addition, in the present invention, a fermented food itself, prepared by adding Akkermansia muciniphila, can be used for the purpose of preventing or alleviating a metabolic disease occurring or exacerbated due to a high fat diet.

Abstract: Provided is a method of diagnosing diabetes, atrial fibrillation, cardiomyopathy, liver cancer, cirrhosis, dementia, depression, Parkinson's disease, or atopic dermatitis, including (a) extracting DNAs from vesicles isolated from samples of a normal individual and a subject; (b) performing PCR (Polymerase Chain Reaction) on the extracted DNA using a pair of primers prepared based on a gene sequence present in 16S rDNA to obtain each PCR product; and (c) determining a case in which a content of vesicles derived from bacteria of the genus Rothia is lower than that of the normal individual sample, as one or more diseases selected from the group consisting of diabetes, atrial fibrillation, cardiomyopathy, liver cancer, cirrhosis, dementia, depression, Parkinson's disease, and atopic dermatitis, through quantitative analysis of the PCR product.

Abstract: Provided are vesicles derived from bacteria of the genus Deinococcus and a use thereof. The vesicles significantly decreased in a clinical sample obtained from a patient with cancer, an inflammatory disease, and dementia, compared with a normal individual, and when the vesicles isolated from the strain were administered, the secretion of inflammation mediators caused by pathogenic vesicles such as E. coli-derived vesicles was considerably inhibited, and vesicles derived from bacteria of the genus Deinococcus significantly inhibit cranial nerve cell damage caused by stress hormones, and therefore, the vesicles derived from bacteria of the genus Deinococcus according to the presently claimed subject matter may be effectively used to develop a method of diagnosing cancer, an inflammatory disease, and/or dementia, and a composition for preventing, alleviating, or treating cancer, an inflammatory disease, and/or a cranial nerve disease.

Abstract: The present invention relates to vesicles derived from bacteria belonging to the genus Sphingomonas and a use thereof, the present inventors experimentally confirmed that the vesicles were significantly decreased in clinical samples of patients with hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain tumors, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis as compared to normal individuals, and when vesicles isolated from the strain were administered, the secretion of inflammatory mediators by pathogenic vesicles such as E.

Abstract: Provided is a method of diagnosing or treating a disease in a subject using the vesicles derived from bacteria of the genus Rhodococcus. The vesicles are significantly decreased in a clinical sample obtained from a patient with lung cancer, pancreatic cancer, bile duct cancer, breast cancer, bladder cancer, lymphoma, diabetes, stroke, myocardial infarction, asthma, COPD, and dementia, compared with a normal individual, and administration of the vesicles to the patient inhibits the secretion of inflammation mediators caused by pathogenic vesicles such as E.

Abstract: Provided are vesicles derived from bacteria of the genus Weissella and a use thereof. The present inventors experimentally identified that vesicles derived from bacteria of the genus Weissella effectively suppress the secretion of inflammatory mediators from pathogenic vesicles inducing inflammation. Thus, it is expected that the vesicles derived from bacteria of the genus Weissella according to the presently claimed subject matter will be advantageously used for the purpose of developing a composition for preventing, alleviating, or treating inflammatory diseases.

Abstract: Provided are a method for preventing, improving, or treating a neurological disorder, mental disorder, senescence, or symptoms thereof, comprising administering to a subject in need thereof vesicles derived from Lactobacillus paracasei as an active ingredient, and a pharmaceutical or functional food composition comprising the vesicles.

Abstract: The present invention relates to vesicles derived from bacteria of the genus Propionibacterium and a use thereof. It was experimentally confirmed that the production of vesicles derived from bacteria of the genus Propionibacterium was increased in the body by a high-fat diet rather than a high-carbohydrate diet; the vesicles were significantly reduced in the blood of patients with cancers, such as breast cancer and liver cancer, inflammation diseases, such as asthma and atopic dermatitis, and metabolic diseases, such as diabetes and liver cirrhosis, compared with normal persons; and the vesicles inhibited the secretion of inflammatory mediators by pathogenic vesicles, inhibited the apoptosis of keratinocytes, and increased the expression of an androgen receptor in the body.

Abstract: Provided are vesicles derived from bacteria of the genus Corynebacterium and a use thereof. The present inventors experimentally identified that vesicles derived from bacteria of the genus Corynebacterium were in reduced levels in clinical samples of patients with cirrhosis, stroke, diabetes, asthma, atopic dermatitis, depression, breast cancer, dementia, and nasal polyps, and effectively suppress the secretion of inflammatory mediators from pathogenic vesicles inducing inflammation. Thus, it is expected that the vesicles derived from bacteria of the genus Corynebacterium according to the presently claimed subject matter will be advantageously used as a composition for prevention or treatment of inflammatory diseases including cirrhosis, stroke, diabetes, asthma, atopic dermatitis, depression, breast cancer, dementia, nasal polyps, and the like.

Abstract: The present invention relates to a centrifugal force-based nanoparticle separation apparatus and method. Specifically, the present invention is based on having a low centrifugal force and a small size, and may thus separate nanovesicles unrelated to antibody specificity in a short time and without using an ultracentrifuge. Further, the present invention requires no additional professional personnel and enables accurate fluid measurement by integrating and automating all processes after sample injection, and may thus reduce the loss of nanovesicles.

Abstract: The present invention relates to a method of diagnosing Alzheimer's dementia by bacterial metagenomic analysis, and more particularly, to a method of diagnosing Alzheimer's dementia and mild cognitive impairment by analyzing an increase or decrease in contents of specific bacterial extracellular vesicles by performing bacterial metagenomic analysis using normal person and subject-derived samples. The extracellular vesicles secreted from bacteria present in the environment are absorbed into the body and penetrate into brain tissue to have a direct influence on a cognitive function such as Alzheimer's dementia, and since Alzheimer's dementia is difficult to be diagnosed early before symptoms are shown, effective treatment is difficult.

Abstract: The present invention relates to a Leuconostocholzapfelii strain for improvement an intestinal function and a use thereof, since the Leuconostoc holzapfelii strain of the present invention can effectively improve the function of an intestine, application to various fields such as various food compositions, pharmaceutical compositions, compositions for animal feed, etc., including functional food composition, is expected.

Abstract: The present invention relates to an immunomodulator for the prevention or treatment of an allergic disease caused by house dust mite-derived allergens. Particularly, the present invention provides an immunomodulatory pharmaceutical composition comprising as an effective ingredient a bacteria extracellular vesicle containing an allergens derived from North American house dust mite or European house dust mite, and a preparation method therefor.

Abstract: Provided is a method of diagnosing head and neck cancer by analyzing an increase or decrease in content of specific bacteria-derived extracellular vesicles through bacterial metagenomic analysis using normal individual- and subject-derived samples, wherein the risk of head and neck cancer can be diagnosed through metagenomic analysis of bacteria-derived extracellular vesicles using a human body-derived sample, and thus a risk group of head and neck cancer can be diagnosed early and predicted, thereby delaying the onset of head and neck cancer or preventing the onset of head and neck cancer through appropriate management, and even after head and neck cancer occur, early diagnosis for head and neck cancer can be implemented, thereby lowering the incidence of head and neck cancer and increasing therapeutic effects.